Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells

Bingsen Zhou, Shu Mi, Xueli Mo, Jennifer Shih, Jeffery Tsai, Edward Hu, Margaret Hsu, Kristie Kay, Yun Yen

Research output: Contribution to journalArticle

23 Citations (Scopus)

Abstract

Gemcitabine (Gem) is a deoxycytidine analogue whose active metabolite, dFdCTP, blocks DNA elongation and has a cytotoxic effect. Hydroxyurea (HU) is an S-phase specific inhibitor of ribonucleotide reductase (RR) with a broad spectrum of antitumor effects. We report here that low-dose HU enhanced the activity of Gem in a time- and sequence-dependent manner. Exposure of human oropharyngeal carcinoma KB cells to HU followed by the addition of Gem at various times significantly enhanced cytotoxicity when compared to controls. The greatest enhancement of cytotoxicity occurred when Gem was added 8 hours after HU. By treating KB cells with radiolabeled-Gem following HU treatment, we further confirmed that the incorporation of dFdCTP into DNA increased 6-fold over control reactions under these conditions. The mechanism of the time- and sequence-dependent enhancement is associated with a decrease in hRRM2 RNA, protein, and activity between 4 and 8 hours. The subsequent depletion of dNTP pools allows for increased incorporation of dFdCTP into cells arrested in S-phase, resulting in higher levels of cytotoxicity than either treatment alone.

Original languageEnglish
Pages (from-to)1369-1378
Number of pages10
JournalAnticancer Research
Volume22
Issue number3
Publication statusPublished - Aug 14 2002
Externally publishedYes

Fingerprint

gemcitabine
KB Cells
Hydroxyurea
S Phase
Ribonucleotide Reductases
Deoxycytidine
DNA
RNA
Carcinoma

Keywords

  • Drug resistance
  • Gemcitabine
  • Hydroxyurea
  • Ribonucleotide reductase
  • Triphosphate pools

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. / Zhou, Bingsen; Mi, Shu; Mo, Xueli; Shih, Jennifer; Tsai, Jeffery; Hu, Edward; Hsu, Margaret; Kay, Kristie; Yen, Yun.

In: Anticancer Research, Vol. 22, No. 3, 14.08.2002, p. 1369-1378.

Research output: Contribution to journalArticle

Zhou, B, Mi, S, Mo, X, Shih, J, Tsai, J, Hu, E, Hsu, M, Kay, K & Yen, Y 2002, 'Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells', Anticancer Research, vol. 22, no. 3, pp. 1369-1378.
Zhou B, Mi S, Mo X, Shih J, Tsai J, Hu E et al. Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. Anticancer Research. 2002 Aug 14;22(3):1369-1378.
Zhou, Bingsen ; Mi, Shu ; Mo, Xueli ; Shih, Jennifer ; Tsai, Jeffery ; Hu, Edward ; Hsu, Margaret ; Kay, Kristie ; Yen, Yun. / Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells. In: Anticancer Research. 2002 ; Vol. 22, No. 3. pp. 1369-1378.
@article{15c22e27516b43979dfa51242616d4bf,
title = "Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells",
abstract = "Gemcitabine (Gem) is a deoxycytidine analogue whose active metabolite, dFdCTP, blocks DNA elongation and has a cytotoxic effect. Hydroxyurea (HU) is an S-phase specific inhibitor of ribonucleotide reductase (RR) with a broad spectrum of antitumor effects. We report here that low-dose HU enhanced the activity of Gem in a time- and sequence-dependent manner. Exposure of human oropharyngeal carcinoma KB cells to HU followed by the addition of Gem at various times significantly enhanced cytotoxicity when compared to controls. The greatest enhancement of cytotoxicity occurred when Gem was added 8 hours after HU. By treating KB cells with radiolabeled-Gem following HU treatment, we further confirmed that the incorporation of dFdCTP into DNA increased 6-fold over control reactions under these conditions. The mechanism of the time- and sequence-dependent enhancement is associated with a decrease in hRRM2 RNA, protein, and activity between 4 and 8 hours. The subsequent depletion of dNTP pools allows for increased incorporation of dFdCTP into cells arrested in S-phase, resulting in higher levels of cytotoxicity than either treatment alone.",
keywords = "Drug resistance, Gemcitabine, Hydroxyurea, Ribonucleotide reductase, Triphosphate pools",
author = "Bingsen Zhou and Shu Mi and Xueli Mo and Jennifer Shih and Jeffery Tsai and Edward Hu and Margaret Hsu and Kristie Kay and Yun Yen",
year = "2002",
month = "8",
day = "14",
language = "English",
volume = "22",
pages = "1369--1378",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "3",

}

TY - JOUR

T1 - Time and sequence dependence of hydroxyurea in combination with gemcitabine in human KB cells

AU - Zhou, Bingsen

AU - Mi, Shu

AU - Mo, Xueli

AU - Shih, Jennifer

AU - Tsai, Jeffery

AU - Hu, Edward

AU - Hsu, Margaret

AU - Kay, Kristie

AU - Yen, Yun

PY - 2002/8/14

Y1 - 2002/8/14

N2 - Gemcitabine (Gem) is a deoxycytidine analogue whose active metabolite, dFdCTP, blocks DNA elongation and has a cytotoxic effect. Hydroxyurea (HU) is an S-phase specific inhibitor of ribonucleotide reductase (RR) with a broad spectrum of antitumor effects. We report here that low-dose HU enhanced the activity of Gem in a time- and sequence-dependent manner. Exposure of human oropharyngeal carcinoma KB cells to HU followed by the addition of Gem at various times significantly enhanced cytotoxicity when compared to controls. The greatest enhancement of cytotoxicity occurred when Gem was added 8 hours after HU. By treating KB cells with radiolabeled-Gem following HU treatment, we further confirmed that the incorporation of dFdCTP into DNA increased 6-fold over control reactions under these conditions. The mechanism of the time- and sequence-dependent enhancement is associated with a decrease in hRRM2 RNA, protein, and activity between 4 and 8 hours. The subsequent depletion of dNTP pools allows for increased incorporation of dFdCTP into cells arrested in S-phase, resulting in higher levels of cytotoxicity than either treatment alone.

AB - Gemcitabine (Gem) is a deoxycytidine analogue whose active metabolite, dFdCTP, blocks DNA elongation and has a cytotoxic effect. Hydroxyurea (HU) is an S-phase specific inhibitor of ribonucleotide reductase (RR) with a broad spectrum of antitumor effects. We report here that low-dose HU enhanced the activity of Gem in a time- and sequence-dependent manner. Exposure of human oropharyngeal carcinoma KB cells to HU followed by the addition of Gem at various times significantly enhanced cytotoxicity when compared to controls. The greatest enhancement of cytotoxicity occurred when Gem was added 8 hours after HU. By treating KB cells with radiolabeled-Gem following HU treatment, we further confirmed that the incorporation of dFdCTP into DNA increased 6-fold over control reactions under these conditions. The mechanism of the time- and sequence-dependent enhancement is associated with a decrease in hRRM2 RNA, protein, and activity between 4 and 8 hours. The subsequent depletion of dNTP pools allows for increased incorporation of dFdCTP into cells arrested in S-phase, resulting in higher levels of cytotoxicity than either treatment alone.

KW - Drug resistance

KW - Gemcitabine

KW - Hydroxyurea

KW - Ribonucleotide reductase

KW - Triphosphate pools

UR - http://www.scopus.com/inward/record.url?scp=0036323457&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036323457&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - 1369

EP - 1378

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 3

ER -